To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)
Conditions: Non-small Cell Lung Cancer Interventions: Drug: cadonilimab Sponsors: Guangzhou Institute of Respiratory Disease Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
Adibelimab, Famitinib and Chemotherapy for Advanced NSCLC After PD-1 Inhibitor Failure
Conditions: Non Small Cell Lung Cancer Interventions: Drug: Adibelimab Sponsors: Second Affiliated Hospital of Xi ' an Jiaotong University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 29, 2024 Category: Research Source Type: clinical trials
Relationship Between Hand Dynamometer Measurements, PFT, and mFI With Postoperative Outcomes
Conditions: Complication,Postoperative; Lung Cancer Interventions: Device: Hand Dynamometer; Diagnostic Test: Pulmonary Function Test; Other: Modified Frailty Index Sponsors: Atat ürk Chest Diseases and Chest Surgery Training and Research Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 29, 2024 Category: Research Source Type: clinical trials
Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer
Conditions: Advanced Cancer; Olanzapine; Progression Free Survival Interventions: Drug: Olanzapine 2.5 MG; Drug: Standard anti-tumor treatment; Dietary Supplement: Nutritional advice Sponsors: Qinghai Red Cross Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 29, 2024 Category: Research Source Type: clinical trials
Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
Conditions: Solid Tumor, Adult; Bladder Cancer; Urothelial Carcinoma; Triple-negative Breast Cancer; Lung Cancer; Colorectal Cancer; Gastric Cancer; Ovarian Cancer; Pancreatic Cancer Interventions: Drug: Diagnostic Test: MNPR-101-DFO*-89Zr PET Scan Sponsors: Monopar Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 29, 2024 Category: Research Source Type: clinical trials
The MyLungHealth Study Protocol: Engaging Patients to Enable Interoperable Lung Cancer Decision Support at Scale
Conditions: Lung Cancer; Lung Neoplasms/Diagnosis Interventions: Behavioral: MyLungHealth; Behavioral: DecisionPrecision+ Sponsors: University of Utah Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 29, 2024 Category: Research Source Type: clinical trials
A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients
Conditions: Non-squamous Non-small Cell Lung Cancer Interventions: Drug: Adebrelimab + SHR-8068 + Pemetrexed + Carboplatin; Drug: Camrelizumab + Pemetrexed + Carboplatin; Drug: Adebrelimab + Pemetrexed + Carboplatin Sponsors: Shanghai Shengdi Pharmaceutical Co., Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 28, 2024 Category: Research Source Type: clinical trials
Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure
Conditions: Non-Squamous Non-Small Cell Lung Cancer Interventions: Drug: Serplulimab; Drug: Bevacizumab Biosimilar HLX04; Drug: Pemetrexed; Drug: Carboplatin Sponsors: Henan Cancer Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 28, 2024 Category: Research Source Type: clinical trials
AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)
Conditions: Thoracic Tumors; Non-small Cell Lung Cancer Interventions: Drug: AMG 193; Drug: Carboplatin; Drug: Paclitaxel; Drug: Pembrolizumab; Drug: Pemetrexed; Drug: Sotorasib Sponsors: Amgen Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2024 Category: Research Source Type: clinical trials
A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)
Conditions: Non-Small Cell Lung Cancer Interventions: Drug: Durvalumab; Drug: Sotorasib Sponsors: Memorial Sloan Kettering Cancer Center; Amgen Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2024 Category: Research Source Type: clinical trials
Study to Evaluate LB-LR1109 for the Treatment of Solid Tumors
Conditions: Non-small Cell Lung Cancer(NSCLC); Head and Neck Squamous Cell Carcinoma(HNSCC); Renal Cell Carcinoma(RCC); Urothelial Carcinoma; Malignant Melanoma Interventions: Drug: LB-LR1109 Sponsors: LG Chem Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2024 Category: Research Source Type: clinical trials
Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy
Conditions: Extensive-stage Small-cell Lung Cancer Interventions: Drug: Adebrelimab, Irinotecan Liposome (II); Drug: Adebrelimab, Irinotecan Liposome (II), Famitinib Sponsors: Baohui Han Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2024 Category: Research Source Type: clinical trials
tislelizUMaB in canceR Patients With molEcuLar residuaL Disease
Conditions: Cancer; Lung Cancer; Colo-rectal Cancer; Pancreas Cancer; Soft Tissue Sarcoma Interventions: Drug: Tislelizumab; Other: Blood sampling; Drug: Placebo Sponsors: Gustave Roussy, Cancer Campus, Grand Paris; BeiGene; C2i Genomics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2024 Category: Research Source Type: clinical trials
Effect of Low-dose Radiotherapy on Tumor Immune Microenvironment in Oligometastases of NSCLC After Immunotherapy
Conditions: Low-dose Radiotherapy; Tumor Microenvironment; Non-Small Cell Lung Cancer Interventions: Radiation: low dose radiotherapy Sponsors: Hetian District People ' s Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 26, 2024 Category: Research Source Type: clinical trials
Distributed Learning of Edic and CardIac Dose Effects in Lung Cancer
Conditions: NSCLC Sponsors: The Netherlands Cancer Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 26, 2024 Category: Research Source Type: clinical trials
